Synchrogenix appoints two new global submissions directors
Synchrogenix Information Strategies, a regulatory writing company headquartered in Wilmington, Del., has added two new global submissions directors: Kelley Hill and Aaron Bernstein.
Kelley Hill brings over 16 years of pharmaceutical experience in drug development to Synchrogenix. Hill's experience extends from target identification through regulatory submissions and post-marketing activities with particular expertise in rare diseases, orphan drugs and oncology. Previously, she has been responsible for managing the medical and regulatory writing activities for multiple projects across 10 development programs.
Dr. Aaron Bernstein is a regulatory writing and business analyst expert with over 20 years of experience. Bernstein has been instrumental in developing and leading writing teams for the submission of clinical and regulatory documents to health authorities worldwide. His therapeutic expertise includes metabolic diseases, HIV/AIDS and cardiology. He will be joining Synchrogenix to pioneer the new office location in Bloomfield, N.J.